Resother Pharma initiates First in Human studies with RTP-026

ResoTher Pharma today announced that the company has received approval to initiate human clinical development with RTP-026, the company’s lead peptide drug candidate.The phase I trial will be conducted at a clinical site in Liege, Belgium where intravenous infusion of...

read more

ResoTher Pharma appoints Samra Sanni as VP of Research

ResoTher Pharma is pleased to announce the appointment of Samra Sanni, PhD, as Vice President, Drug Research as of today September 15th 2021. Samra will be responsible for preclinical drug research and development of novel drug molecules.  Samra has a successful track...

read more

ResoTher Pharma strengthens its leadership team

ResoTher Pharma is pleased to announce the following changes to its leadership team to further support the growth and development of the company. Teis Vester, MSc., will take on the role of Chief Financial Officer from August 16th, 2021, replacing co-founder Jeppe...

read more

ResoTher Pharma announces changes to its Board of Directors

ResoTher Pharma ApS, Holte, Denmark, announces today that the shareholders has elected two new members to the company's Board of Directors at the Annual General Meeting held May 31st, 2021. Thomas Feldhus, MBA, a Copenhagen-based life science executive joins the...

read more

ResoTher Pharma announces capital raise of DKK 38.8M

Press release: ResoTher Pharma ApS, a Danish biotech company, today announces the successful completion of a new share issue. The transaction was completed with share subscriptions from existing and new investors in collaboration with North Finance A/S, a Danish...

read more

ResoTher Pharma R&D update

ResoTher Pharma is pleased to announce that we have completed IND-enabling toxicology studies of the lead drug RTP-026. The studies have been carried out in collaboration with Charles River Labs and Merck Bioreliance, both leading global providers of GLP-certified...

read more

Anthony Mathur, MD joins our Scientific Advisory Board

ResoTher Pharma is pleased to announce the addition of Dr Anthony Mathur to its Scientific Advisory Board. Dr Mathur is Professor and Clinical Director for Interventional Cardiology at Barts Health and a Director at the Centre for Cardiovascular Medicine and Device...

read more

ResoTher Pharma closes private financing round

ResoTher Pharma  announces today that the company has closed a financing round with local and European private investors, leading to proceeds of 16.5M DKK in combined financing, consisting of the equity contributoin as well as three non-dilutive grants from Barts...

read more